SNA
70
-2
SCHW
50
-2
CNX
69
-4
DIS
52
5
PHM
55
-2
K
59
6
CME
56
-2
ISRG
67
-3
IP
71
14
MTCH
31
-6
FAST
60
-3
JBHT
59
-3
INTU
43
-5
MSFT
46
-11
CMI
49
-2
TRV
49
-4
ES
55
2
BRK.B
36
-2
ZION
57
-4
ORCL
54
-8
SNA
70
-2
SCHW
50
-2
CNX
69
-4
DIS
52
5
PHM
55
-2
K
59
6
CME
56
-2
ISRG
67
-3
IP
71
14
MTCH
31
-6
FAST
60
-3
JBHT
59
-3
INTU
43
-5
MSFT
46
-11
CMI
49
-2
TRV
49
-4
ES
55
2
BRK.B
36
-2
ZION
57
-4
ORCL
54
-8
Financhill
Back

PeptiDream 10K Form

Buy
67

PPTDF
PeptiDream

Last Price:
17.00
Seasonality Move:
2.69%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive PPTDF News And Ratings

See the #1 stock for the next 7 days that we like better than PPTDF

PPTDF Financial Statistics

Sales & Book Value

Annual Sales: $204.65M
Cash Flow: $-6.87M
Price / Cash Flow: 0
Annual Sales: $2.82
Price / Book: 6.03

Profitability

EPS (TTM): 1.08530
Net Income (TTM): $140.85M
Gross Margin: $122.73M
Return on Equity: 51.02%
Return on Assets: 29.47%

PeptiDream Earnings Forecast

Key PeptiDream Financial Ratios

  • The Gross Profit Margin over the past 12 years for PPTDF is 59.97%.
  • The Selling, General & Administrative Expenses for PPTDF have been equal to 25.27% of Gross Profit Margin.
  • The Research & Development expenses have been 10.99% of Revenue.
  • The Interest Expense is 74.21% of Operating Income.
  • The Net Earning history of PPTDF is 10.57% of Total Revenues.
  • Per Share Earnings over the last 12 years have been positive in 7 years.

PeptiDream Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: OTCM
Industry: Biotechnology
Sector: Health Care
Current Symbol: PPTDF
Website: peptidream.com

Debt

Debt-to-Equity Ratio: 0.36
Current Ratio: 3.39
Quick Ratio: 3.19

Price-to-Earnings

Trailing P/E Ratio: 102.02
Forward P/E Ratio: 0

PPTDF Technical Analysis vs Fundamental Analysis

Buy
67
PeptiDream (PPTDF) is a Buy

Is PeptiDream a Buy or a Sell?

  • PeptiDream stock is rated a Buy
    The current PeptiDream [PPTDF] share price is $17.00. The Score for PPTDF is 67, which is 34% above its historic median score of 50, and infers lower risk than normal.